Format

Send to

Choose Destination
See comment in PubMed Commons below
Ther Adv Med Oncol. 2012 Sep;4(5):271-9. doi: 10.1177/1758834012446008.

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer.

Author information

1
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA.

Abstract

Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.

KEYWORDS:

chemotherapy; drug delivery; folfirinox; gemcitabine; pancreatic cancer; resistance

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center